Stein Steven H, an insider at Incyte Corp (INCY), purchased 107,075 shares of the company on November 4, 2025, at a price of $95.76 per share. This transaction amounts to a total value of $10.25 million. Following this purchase, Stein now holds 107,075 shares of Incyte.
Incyte Corp, a biopharmaceutical company based in Wilmington, Delaware, focuses on the discovery, development, and commercialization of proprietary therapeutics. The company operates in two therapeutic areas: Hematology/Oncology and Inflammation and Autoimmunity. Its hematology and oncology franchise includes six products, such as JAKAFI (ruxolitinib) and MONJUVI (tafasitamab-cxix), and it is supported by a robust pipeline of clinical development programs.
This insider transaction may be perceived as a positive signal, as executives often possess insights into their company's future performance. However, it is essential for investors to consider insider transactions as part of a broader analysis that includes other fundamental and technical factors. The move underscores the need for investors to look beyond isolated transactions and examine patterns of insider activity across multiple executives and time frames.
Incyte currently has a market capitalization of $20.5 billion and a P/E ratio of 17.24. The company's earnings per share (EPS) stands at 5.91. Upcoming earnings reports are anticipated, with estimates of $1.63 per share and $1.3 billion in revenue for April 26, 2026, and $1.68 per share with the same revenue estimate for July 26, 2026.